Xuanzhu Biopharmaceutical Co (FRA:V59) Other Current Receivables: €0.76 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V59 Xuanzhu Biopharmaceutical Co Ltd FRA:V59
11 GF Score
Price €1.35
! 1 Warning Sign
View Full Analysis

What is Xuanzhu Biopharmaceutical Co Other Current Receivables?

Xuanzhu Biopharmaceutical Co FRA:V59 +3.37% 11 Other Current Receivables is €0.76 Mil as of Dec. 2025. GuruFocus rates FRA:V59 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Xuanzhu Biopharmaceutical Co's Other Current Receivables for the quarter that ended in Dec. 2025 was €0.76 Mil.

Xuanzhu Biopharmaceutical Co's quarterly Other Current Receivables declined from Dec. 2024 (€1.77 Mil) to Jun. 2025 (€1.75 Mil) but then stayed the same from Jun. 2025 (€1.75 Mil) to Dec. 2025 (€0.76 Mil).

Xuanzhu Biopharmaceutical Co's annual Other Current Receivables increased from Dec. 2023 (€1.74 Mil) to Dec. 2024 (€1.77 Mil) but then declined from Dec. 2024 (€1.77 Mil) to Dec. 2025 (€0.76 Mil).

Xuanzhu Biopharmaceutical Co Other Current Receivables Related Terms

Xuanzhu Biopharmaceutical Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Xuanzhu Biopharmaceutical Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xuanzhu Biopharmaceutical Co Other Current Receivables Chart

Xuanzhu Biopharmaceutical Co Annual Data
Trend Dec23 Dec24 Dec25
Other Current Receivables
1.74 1.77 0.76

Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables 1.74 0.00 1.77 1.75 0.76
FRA:V59
11GF Score
Xuanzhu Biopharmaceutical Co Ltd FRA:V59
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xuanzhu Biopharmaceutical Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.76 Mil mean?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a Other Current Receivables of €0.76 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Xuanzhu Biopharmaceutical Co and its competitors.
Is Xuanzhu Biopharmaceutical Co's Other Current Receivables too high?
Xuanzhu Biopharmaceutical Co's current Other Current Receivables is €0.76 Mil. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's Other Current Receivables compare to ZTS?
Xuanzhu Biopharmaceutical Co's Other Current Receivables of €0.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. Xuanzhu Biopharmaceutical Co's current Other Current Receivables is €0.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a current Other Current Receivables of €0.76 Mil. The current Other Current Receivables is €0.76 Mil. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (FRA:V59), the current Other Current Receivables is €0.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xuanzhu Biopharmaceutical Co Business Description

Other Exchanges 02575:Hong Kong
Address Zhubang 2000 Business Center, 2107, Building 2, Balizhuang Xili, Chaoyang District, Beijing, CHN
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score

Get the complete analysis for FRA:V59

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.35
Price